Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhishi Daozhi Pill (also known as Zhishi Daozhi Wan) is a traditional Chinese medicine (TCM) herbal formula composed of eight herbs, including *Rheum officinale Baill.* (rhubarb). It is primarily used to treat gastrointestinal disorders characterized by food stagnation and constipation. The formula works through a multi-target approach that includes strengthening the spleen, regulating the stomach, and enhancing digestion. Its mechanism of action involves the regulation of gut microbiota, stimulation of colonic mucus production, and enhancement of intestinal peristalsis. Research has linked its therapeutic effects to the modulation of biological targets such as 5-hydroxytryptamine (5-HT), vasoactive intestinal peptide (VIP), and aquaporin-3 (AQP3). Taixing People's Hospital has conducted clinical trials evaluating the formula specifically for constipation-predominant irritable bowel syndrome (IBS-C) in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhishi Daozhi Pill.